Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Company Summary - Hubei Jianxiang Biopharmaceutical Co., Ltd. is now authorized to market Acetate Leuprolide, a GnRH agonist, which effectively suppresses the secretion of gonadotropins when administered continuously at therapeutic doses [1] - The approved indications for Acetate Leuprolide in China include treatment for endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

Core Viewpoint - Sichuan Shuangma (000935) announced that its subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Group 1: Company Developments - The approval pertains to Acetate Leuprolide, a Gonadotropin-Releasing Hormone (GnRH) agonist, which effectively suppresses the secretion of gonadotropins when administered at therapeutic doses [1] - The drug is currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

格隆汇10月16日丨四川双马(000935.SZ)公布，控股子公司湖北健翔生物制药有限公司（简称"湖北健 翔"）于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。醋酸 亮丙瑞林是一种促性腺激素释放激素（GnRH）激动剂，治疗剂量下持续给药可有效抑制促性腺激素的 分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经前乳腺癌、中 枢性性早熟的治疗。 ...

四川双马(000935.SZ)公告称，公司控股子公司湖北健翔生物制药有限公司近日获得国家药品监督管理 局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。该原料药已符合国家相关原料药审评技术 要求，可在国内市场进行生产销售，进一步丰富了公司产品线，强化了公司在国内原料药细分领域的竞 争优势。但需注意医药产业特点及市场环境等因素影响，存在不确定性。 ...

Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Group 1: Company Developments - Hubei Jianxiang has obtained the approval for Acetate Leuprolide, which is a Gonadotropin-Releasing Hormone (GnRH) agonist [1] - The drug is effective in suppressing the secretion of gonadotropins when administered at therapeutic doses [1] Group 2: Market Applications - Acetate Leuprolide is currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

智通财经APP讯，四川双马(000935.SZ)公告，公司控股子公司湖北健翔生物制药有限公司(简称"湖北健 翔")于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。 公告显示，醋酸亮丙瑞林是一种促性腺激素释放激素(GnRH)激动剂，治疗剂量下持续给药可有效抑制 促性腺激素的分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经 前乳腺癌、中枢性性早熟的治疗。 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-45 四川和谐双马股份有限公司 关于控股子公司湖北健翔 获得化学原料药上市申请批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（简称"公司"）控股子公司湖北健翔生物制药 有限公司（简称"湖北健翔"）于近期获得国家药品监督管理局签发的醋酸亮丙 瑞林《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、本次获得化学原料药上市申请批准通知书的具体情况 1、化学原料药名称 （1）通用名称: 醋酸亮丙瑞林 （2）英文名/拉丁名: Leuprorelin Acetate 2、登记号: Y20240000206 3、受理号: CYHS2460227 4、包装规格：50g/瓶/袋 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7、生产企业： （1）名称：湖北健翔生物制药有限公司 （2）地址：湖北咸宁咸安经济开发区绿山路 9 号 二 ...

Core Viewpoint - The company, Sichuan Shuangma, clarified on October 15 that it does not have any investments in the rare earth industry [1] Group 1 - The company made a statement on an interactive platform regarding its investment activities [1]

Core Viewpoint - Sichuan Shuangma (000935) has clarified that the company is not involved in any investments related to the rare earth industry [1] Company Summary - On October 15, Sichuan Shuangma stated on an interactive platform that it does not engage in investments in the rare earth sector [1]

格隆汇10月15日丨四川双马(000935.SZ)在互动平台表示，公司不涉及对稀土产业的投资。 ...